# Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI

> **NIH VA I01** · JAMES J PETERS VA  MEDICAL CENTER · 2022 · —

## Abstract

Persons with chronic spinal cord injury (SCI) have markedly reduced bone mass and the loss of skeletal
architectural integrity, which predisposes them to low-impact fractures. Currently, there is no practical treatment
to reverse the severe bone loss in persons with chronic SCI. In the proposed study, a dual pharmacological
intervention will be tested to improve bone health. Restoration of bone mass below the level of injury would be
expected to reduce the morbidity associated with fractures and permit safer participation in upright activities.
Quality of life would be substantially improved because of the ability to engage more securely in activities of daily
living and to integrate into the community. Despite the depressed skeletal activity below the level of lesion in
persons with chronic SCI, net bone loss occurs because resorption exceeds formation, with a difference
between these rates in those with SCI being greater than that observed in the able-bodied population. Thus, it
would be anticipated to be of value in persons with chronic SCI to increase bone turnover with the objective to
increase bone formation over that of bone resorption. In a preclinical study that administered an anti-sclerostin
antibody to rats 12 weeks after complete spinal cord transection bone, mineral density (BMD) was almost fully
restored at the distal femoral metaphysis, with improved bone structure, and mechanical strength; in contrast,
vehicle-treated animals after complete spinal transection had a marked reduction in distal femoral metaphysis
BMD and a deterioration in bone structure and mechanical strength. When used to treat postmenopausal
osteoporosis, romosozumab, a human monoclonal anti-sclerostin antibody, was more effective to increase
bone mineral density (BMD) and to reduce fracture than any other anti-resorptive or bone-anabolic agent, and
this effect was also evident for the appendicular skeleton, which is the site in individuals with chronic SCI of
greatest bone loss and most frequent fracture. Because of the absence of clinical options available for the
treatment of osteoporosis in individuals with chronic paralysis, the investigators have proposed to test an
antagonist of sclerostin, which is a potent bone anabolic agent with proven efficacy in treating women with
postmenopausal osteoporosis, to improve bone mass and reduce fragility fractures.
 Thirty-nine male and female subjects with chronic, motor-complete SCI (>3 post injury, American Spinal
Injury Association Impairment Scale A & B) between the ages of 18 and 50 years old who have aBMD at the
distal femur at the distal femur ≥0.7 g/cm2 but ≤1.0 g/cm2 will be recruited for participation in a randomized,
double-blind, placebo-controlled, parallel group clinical trial. The outcome measures of the proposed study are
bone mineral density (BMD) by peripheral quantitative computed tomography (pQCT) and dual energy x-ray
absorptiometry (DXA), and biochemical markers of bone resorption and formation. ...

## Key facts

- **NIH application ID:** 10418624
- **Project number:** 5I01RX003415-03
- **Recipient organization:** JAMES J PETERS VA  MEDICAL CENTER
- **Principal Investigator:** CHRISTOPHER P CARDOZO
- **Activity code:** I01 (R01, R21, SBIR, etc.)
- **Funding institute:** VA
- **Fiscal year:** 2022
- **Award amount:** —
- **Award type:** 5
- **Project period:** 2020-06-01 → 2026-06-30

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10418624

## Citation

> US National Institutes of Health, RePORTER application 10418624, Romosozumab to Improve Bone Mineral Density and Architecture in Chronic SCI (5I01RX003415-03). Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/grant/nih/10418624. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*